BioSpace News Archive

Medical claims management innovator Medlogix, today announced that Cindy Pirozzi has joined the organization as the Senior Vice President of Workers’ Compensation Managed Care, where she will be responsible for leading the division’s strategic initiatives including business development, product expansion and customer relations.

MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Asit Parikh, M.D., Ph.D., has been appointed as the company’s president and chief executive officer, effective April 5, 2021.

SAVE THE DATE: Webinar Scheduled for March 23, 2021 @ 11 AM ET as 9 Meters Biopharma, Inc. announced that it will host a research and development day webinar on its clinical development program to treat short bowel syndrome (SBS) on Tuesday, March 23, 2021 at 11:00 am Eastern Time.

Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada

Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, announced that a peer-reviewed manuscript, entitled, “Sigma-2-Receptor Antagonists Rescue Neuronal Dysfunction Induced by Parkinson’s Patient Brain-Derived α-Synuclein,” has been published online in the Journal of Neuroscience Research.

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Jay L. Warner, a 30-year veteran of the healthcare industry, as head of U.S. commercial operations.

– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike protein as a target of potent neutralizing antibodies, but a target that can vary – – Separate research results published in Cell characterize the virulence and antibody response to N439K, a prevalent variant of the SARS-CoV-2 receptor binding motif

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Tuesday, February 23, 2021 , at 4:30 p.m. Eastern Time to review 2020 fourth quarter and full year financial results.

Carevature Medical, Inc. announces a new article that has just been published in PharmacoEconomics, sharing the significant economic impact when Dreal® technology is used to prepare the intervertebral endplates during the common TLIF procedure.

ATCC joins National Institute of Allergy and Infectious Diseases’ team working on preclinical services for HIV therapeutics